A Historic Moment: Our Community at the FDA Advisory Committee for Elamipretide скачать в хорошем качестве

A Historic Moment: Our Community at the FDA Advisory Committee for Elamipretide

In October 2024, the Barth syndrome community gathered in Silver Spring, Maryland, for a historic moment: the U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting to review elamipretide for the treatment of Barth syndrome. For the first time, individuals and families directly affected by this ultra-rare, life-threatening mitochondrial disease shared their lived experiences before the FDA. Parents, patients, clinicians, and advocates spoke with clarity and courage about the urgent need for meaningful treatment options. This meeting represented more than a regulatory milestone. It was a defining moment for our community — an opportunity to ensure that patient voices were heard in the evaluation of a potential therapy developed specifically for Barth syndrome. We are deeply grateful to every speaker, every family, and every advocate who made their voice part of the official record.